Boston Scientific Analyst Price Targets

Wall Street analyst price targets and consensus rating for Boston Scientific (BSX).

Price Target Range — 5 Quarters

Analyst Consensus — 22 Analysts

19Buy

3Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$64Upside to Avg. PT+49.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Barclays	Christopher Pasquale	PT Cut	Equal-Weight	$48→$45
Oct 29, 2026	Jefferies	Matthew Taylor	Downgrade	Buy→Hold	$60→$46
Oct 29, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$66→$48
Oct 29, 2026	Bernstein	—	PT Cut	Outperform	$54→$49
Oct 29, 2026	RBC Capital	Kendall Au	PT Cut	Outperform	$70→$52
Oct 29, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$48→$44
Oct 29, 2026	Leerink Partners	Mike Kratky	PT Cut	Outperform	$55→$50
Oct 29, 2026	UBS	Patrick Wood	PT Cut	Buy	$67→$57
Oct 29, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$48→$45
Oct 29, 2026	Baird	David Rescott	PT Raise	Outperform	$50→$51
Oct 29, 2026	BTIG	Marie Thibault	PT Cut	Buy	$56→$49
Oct 28, 2026	Needham	Mike Matson	PT Cut	Buy	$57→$48
Oct 26, 2026	Stifel	Rick Wise	PT Cut	Buy	$60→$55
Oct 14, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$57→$51
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$48
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$50→$48
Sep 24, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$50→$48
Sep 21, 2026	Oppenheimer	Suraj Kalia	PT Cut	Outperform	$85→$65
Sep 17, 2026	Citigroup	Joanne Wuensch	Downgrade	Buy→Neutral	$57→$50
Sep 9, 2026	BTIG	Marie Thibault	PT Cut	Buy	$60→$56

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45

Barclays analyst Christopher Pasquale maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.

Benzinga Newsdesk

PRO
Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46

Jefferies analyst Matthew Taylor downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $60 to $46.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52

RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $70 to $52.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Neutral and lowers the price target from $48 to $44.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50

Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.

Benzinga Newsdesk

Boston Scientific Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Boston Scientific Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45

PRO
Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46

PRO
Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48

PRO
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52

PRO
Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44

PRO
Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50

People Also Watch

People Also Watch

Boston Scientific Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Boston Scientific Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45

PROJefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46

PROCanaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48

PRORBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52

PROCitigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44

PROLeerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50

People Also Watch

People Also Watch

PRO
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45

PRO
Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46

PRO
Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48

PRO
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52

PRO
Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44

PRO
Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50